In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was $20.01 for the day, down -0.25% from the previous closing price of $20.06. In other words, the price has decreased by -$0.25 from its previous closing price. On the day, 0.75 million shares were traded. TNXP stock price reached its highest trading level at $20.69 during the session, while it also had its lowest trading level at $19.3.
Ratios:
Our analysis of TNXP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.22 and its Current Ratio is at 7.53. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 21 ’25 when Taylor Carolyn E. bought 418 shares for $36.03 per share. The transaction valued at 15,061 led to the insider holds 418 shares of the business.
Treco James bought 250 shares of TNXP for $9,000 on Aug 20 ’25. The Director now owns 250 shares after completing the transaction at $36.00 per share. On May 15 ’25, another insider, LEDERMAN SETH, who serves as the Chief Executive Officer of the company, bought 4,000 shares for $21.55 each. As a result, the insider paid 86,200 and bolstered with 4,005 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 175843888 and an Enterprise Value of 50566580. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.84 while its Price-to-Book (P/B) ratio in mrq is 0.90. Its current Enterprise Value per Revenue stands at 5.144 whereas that against EBITDA is -0.633.
Stock Price History:
The Beta on a monthly basis for TNXP is 1.83, which has changed by 0.250625 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, TNXP has reached a high of $130.00, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is -37.27%, while the 200-Day Moving Average is calculated to be -28.30%.
Shares Statistics:
TNXP traded an average of 1.53M shares per day over the past three months and 1022750 shares per day over the past ten days. A total of 8.77M shares are outstanding, with a floating share count of 8.76M. Insiders hold about 0.08% of the company’s shares, while institutions hold 15.98% stake in the company. Shares short for TNXP as of 1759190400 were 1930715 with a Short Ratio of 1.26, compared to 1756425600 on 1173859. Therefore, it implies a Short% of Shares Outstanding of 1930715 and a Short% of Float of 22.03.
Earnings Estimates
The market rating for Tonix Pharmaceuticals Holding Corp (TNXP) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$3.05, with high estimates of -$3.05 and low estimates of -$3.05.
Analysts are recommending an EPS of between -$10.3 and -$10.3 for the fiscal current year, implying an average EPS of -$10.3. EPS for the following year is -$4.5, with 1.0 analysts recommending between -$4.5 and -$4.5.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 2 analysts. It ranges from a high estimate of $2.5M to a low estimate of $2.1M. As of . The current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.82MFor the next quarter, 2 analysts are estimating revenue of $2.9M. There is a high estimate of $3.6M for the next quarter, whereas the lowest estimate is $2.2M.
A total of 2 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $10.5M, while the lowest revenue estimate was $8.7M, resulting in an average revenue estimate of $9.6M. In the same quarter a year ago, actual revenue was $10.09MBased on 3 analysts’ estimates, the company’s revenue will be $94.17M in the next fiscal year. The high estimate is $203.5M and the low estimate is $31.3M.
